Cenobamate clinical trials
Also written YKP3089 and Xcopri.
How each study uses Cenobamate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Cenobamate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Nov 2019 · XCOPRI · NDA 212839 (FDA, Drugs@FDA)
- European Union
- 26 Mar 2021 · Ontozry · EMEA/H/C/005377 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 1
SK Life Science, Inc. (15) · Ono Pharmaceutical Co. Ltd (2) · Brigham and Women's Hospital (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test Cenobamate, phase 3 first.
- Jan 2027ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.Phase 3 · Ono Pharmaceutical Co. Ltd
- Jan 2027Safety of Cenobamate in Japanese Subjects With Partial Onset SeizuresPhase 2 · Ono Pharmaceutical Co. Ltd
- May 2027Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset EpilepsyPhase 4 · SK Life Science, Inc.
Studies
Open first, then newest update. How each study uses Cenobamate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Cenobamate in the Intensive Care UnitNot yet recruitingEarly Phase 1Brigham and Women's HospitalNCT06352723Written as Cenobamate
- ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.RecruitingPhase 3Ono Pharmaceutical Co. LtdNCT06579573Written as Cenobamate
- Safety of Cenobamate in Japanese Subjects With Partial Onset SeizuresRecruitingPhase 2Ono Pharmaceutical Co. LtdNCT06590896Written as Cenobamate
- Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset EpilepsyActive, not recruitingPhase 4SK Life Science, Inc.NCT06453213Written as Cenobamate
- Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresCompletedPhase 3SK Life Science, Inc.NCT05067634Written as Xcopri
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC SeizuresCompletedPhase 3SK Life Science, Inc.NCT03678753Written as Cenobamate
- Cenobamate Open-Label Extension Study for YKP3089C025CompletedPhase 3SK Life Science, Inc.NCT03961568Written as Cenobamate
- Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POSCompletedPhase 3SK Life Science, Inc.NCT04557085Written as Cenobamate
- Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset SeizuresCompletedPhase 1SK Life Science, Inc.NCT04903314Written as Xcopri
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresCompletedPhase 2SK Life Science, Inc.NCT01866111Written as YKP3089
- A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug UsersCompletedPhase 1SK Life Science, Inc.NCT03509285Written as Cenobamate
- A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered OrallyCompletedPhase 1SK Life Science, Inc.NCT05572255Written as Cenobamate
- Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug InteractionsCompletedPhase 1SK Life Science, Inc.NCT03234699Written as Cenobamate
- Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and TabletCompletedPhase 1SK Life Science, Inc.NCT04690751Written as Cenobamate 200Mg Tab Fasted
- Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresCompletedPhase 3SK Life Science, Inc.NCT02535091Written as YKP3089
- Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic ImpairmentCompletedPhase 1SK Life Science, Inc.NCT04791553Written as Cenobamate
- Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset SeizuresCompletedPhase 2SK Life Science, Inc.NCT01397968Written as YKP3089
- Efficacy of YKP3089 in Patients With Photosensitive EpilepsyCompletedPhase 2SK Life Science, Inc.NCT00616148Written as YKP3089
Codes
What other systems call Cenobamate · ClinicalTrials.gg INT001213
- MeSH (NLM) C000654784CenobamateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) P85X70RZWSCENOBAMATEConfirmed FDA, NLM, Wikidata
- RxNorm 2265690One source FDA
- Wikidata Q27286352cenobamateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174837CenobamateOne source FDA
- DrugBank DB06119One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654784 | Cenobamate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P85X70RZWS | CENOBAMATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2265690 | — | One source FDA |
| Wikidata | Q27286352 | cenobamate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174837 | Cenobamate | One source FDA |
| DrugBank | DB06119 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.